MX2013006758A - Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos. - Google Patents

Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.

Info

Publication number
MX2013006758A
MX2013006758A MX2013006758A MX2013006758A MX2013006758A MX 2013006758 A MX2013006758 A MX 2013006758A MX 2013006758 A MX2013006758 A MX 2013006758A MX 2013006758 A MX2013006758 A MX 2013006758A MX 2013006758 A MX2013006758 A MX 2013006758A
Authority
MX
Mexico
Prior art keywords
methods
prostate
hla
binding peptides
peptides derived
Prior art date
Application number
MX2013006758A
Other languages
English (en)
Spanish (es)
Inventor
Toni Weinschenk
Peter Lewandrowski
Stefan Stevanovic
Cecile Gouttefanges
Hans-Georg Rammensee
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MX2013006758A publication Critical patent/MX2013006758A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2013006758A 2010-12-14 2011-11-14 Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos. MX2013006758A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/069675 WO2011073215A2 (en) 2009-12-14 2010-12-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
PCT/EP2011/070024 WO2012079878A2 (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2013006758A true MX2013006758A (es) 2013-08-01

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006758A MX2013006758A (es) 2010-12-14 2011-11-14 Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.

Country Status (9)

Country Link
JP (1) JP6032853B2 (https=)
KR (1) KR20130126671A (https=)
CN (1) CN103547283A (https=)
AU (1) AU2011344652B2 (https=)
CA (1) CA2821582A1 (https=)
MX (1) MX2013006758A (https=)
NZ (1) NZ609916A (https=)
SG (1) SG191154A1 (https=)
WO (1) WO2012079878A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
US10639329B2 (en) * 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018148671A1 (en) * 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2394741A1 (en) * 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
AU2003302820A1 (en) * 2002-12-05 2004-06-30 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
PT2113253E (pt) * 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
SI2119726T2 (en) * 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka

Also Published As

Publication number Publication date
KR20130126671A (ko) 2013-11-20
SG191154A1 (en) 2013-07-31
WO2012079878A2 (en) 2012-06-21
CN103547283A (zh) 2014-01-29
JP6032853B2 (ja) 2016-11-30
NZ609916A (en) 2015-03-27
WO2012079878A3 (en) 2012-08-09
AU2011344652B2 (en) 2015-11-19
CA2821582A1 (en) 2012-06-21
AU2011344652A1 (en) 2013-05-23
JP2014502961A (ja) 2014-02-06

Similar Documents

Publication Publication Date Title
MX2013006758A (es) Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CY1124805T1 (el) Φλαγγελινη roseburia και ανοσοτροποποιηση
CY2024023I2 (el) Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
CL2019002941A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer. (divisional solicitud 201801531)
CY1126819T1 (el) Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη
WO2011073215A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
EA201591801A1 (ru) Лекарственные конъюгаты антител
MX386793B (es) Vacunas individualizadas para el cancer.
ES2681973T3 (es) Respuesta antitumoral contra autoepítopos modificados
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
CL2015000431A1 (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX382293B (es) Predicción de inmunogenicidad en epítopos de células t.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
AR098256A1 (es) Vectores para expresión de antígenos asociados a próstata
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
EP4509616A3 (en) Use of cd36 to identify cancer subjects for treatment
NZ594198A (en) Neil3 peptides and vaccines including the same
PH12019500344A1 (en) Immunotherapy for polyomaviruses